Monte Rosa Therapeutics (GLUE) Cash & Equivalents (2020 - 2026)

Monte Rosa Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $678.1 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 763.48% year-over-year to $678.1 million in Q1 2026; TTM through Mar 2026 was $678.1 million, a 763.48% increase from a year earlier, with the FY2025 full-year figure at $129.9 million, down 65.91% from the prior year.
• Cash & Equivalents advanced to $678.1 million in Q1 2026 per GLUE's latest filing, from $129.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $678.1 million in Q1 2026 and bottomed at $47.0 million in Q2 2023.
• The 5-year median for Cash & Equivalents is $112.4 million (2022), against an average of $176.4 million.
• Across the five-year window, Cash & Equivalents slumped 84.13% in 2022 and soared 763.48% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $54.9 million in 2022, then soared by 133.28% to $128.1 million in 2023, then soared by 197.39% to $381.0 million in 2024, then plunged by 65.91% to $129.9 million in 2025, then jumped by 422.08% to $678.1 million in 2026.
• Per Business Quant, the three latest GLUE Cash & Equivalents figures stand at $678.1 million (Q1 2026), $129.9 million (Q4 2025), and $401.6 million (Q3 2025).